Navidea Biopharmaceuticals Inc. (NAVB) 1.30 $NAVB
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Tue Jul 29, 8:37AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. EDT.
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
Business Wire - Thu Jul 17, 2:44PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. Approximately 79 percent of outstanding shares were represented at the meeting.
Navidea Joins Essex Woodland's Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases
Business Wire - Wed Jul 16, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint enterprise, called R-NAV, LLC, will combine Navidea's proprietary Manocept CD206 macrophage targeting platform and Rheumco's proprietary Tin-117m radioisotope technology to focus on leveraging the platforms across several indications with high unmet medical need:
Accuray Shows Continued Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:25PM CDT
We are also encouraged about Accuray's (ARAY) narrower loss in the 2014-third quarter and upgraded guidance for total revenue for the full fiscal year.
Cyberonics Poised on Favorable Market Trend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 2:20PM CDT
On July 2, we issued an updated research report on Cyberonics Inc. (CYBX).
Thoratec Acquires Irish Implant Systems Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 12:40PM CDT
Thoratec Corp. (THOR) expects to enjoy long-term tax benefits from the Apica acquisition.
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014
Business Wire - Wed Jul 02, 4:06PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 from 8:00 to 9:00 am EDT in New York City.
ABIOMED Acquires Germany's Medical Device Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 12:30PM CDT
The acquisition will solidify ABIOMED's (ABMD) position in intellectual property for axial and expandable pump capabilities
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael Goldberg, M.D., Interim Chief Executive Officer, will participate at the 9th Annual JMP Securities Healthcare Conference June 24-25, 2014 at the Westin New York Grand Central in New York City, NY. Navidea's presentation is on Tuesday, June 24, 2014 at 2:00 PM EDT.
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
U.S. FDA Approves Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy
Business Wire - Fri Jun 13, 11:26AM CDT
--- Lymphoseek now available for multiple patient populations using existing reimbursement codes -
Biotech Stock Mailbag: Vanda, Navidea, Provectus
at The Street - Fri Jun 13, 7:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Navidea (NAVB) Worth Watching: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:46AM CDT
Navidea (NAVB) was a big mover last session, with shares rising over 7% on the day.
Why Navidea Biopharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 2:35PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
Business Wire - Wed Jun 11, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from a post-hoc analysis of patient data from the Company's Phase 3 clinical trial (NEO3-06) of Lymphoseek in head and neck cancer. The ability of Lymphoseek to localize in sentinel lymph nodes is based on its ability to target specific CD206 mannose receptor sites in macrophages, a type of immune cell which resides in high concentration in lymph nodes. In the NEO3-06 Phase 3 study, Lymphoseek localization to lymph nodes showed a strong correlation with a full regional lymph node dissection and pathology analysis with a low false negative rate, a priority in identifying sentinel nodes. Lymphoseek was also observed to home preferentially to pathology-positive nodes at a higher rate than pathology-negative nodes. These results suggest that Lymphoseek not only effectively targets sentinel lymph nodes, but further that its ability to highlight tumor-positive lymph nodes may be augmented mechanistically by the recruitment of macrophages to cancer-harboring lymph nodes.
Navidea Biopharmaceuticals Announces Positive Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Results on Injection Timing and Surgery Across Multiple Solid Tumor Types
Business Wire - Tue Jun 10, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from combined analyses of Phase 3 clinical trials that evaluated Lymphoseek(R) efficacy in lymphatic mapping for identifying pathology-positive lymph nodes across multiple solid tumor types: melanoma, breast cancer and head and neck squamous cell carcinoma. The results indicated that Lymphoseek sensitivity for sentinel lymph node mapping was consistent across the tumor type studies, regardless of whether surgery was conducted on the same day as, or on the day after injection of Lymphoseek. Additionally, for patients with head and neck cancer, Lymphoseek demonstrated a low false negative rate (FNR) of 2.6% (4.6% for same day injection before surgery and 0.0% FNR in patients injected the day prior to surgery). Results from the study comprise part of an sNDA filing for Lymphoseek which is under review by the U.S. Food and Drug Administration.
Navidea Announces Data Demonstrating Potential of Manocept(TM) Platform to Diagnose Rheumatoid Arthritis and Kaposi's Sarcoma
Business Wire - Tue Jun 10, 7:01AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from three research studies performed with collaborators that demonstrate the potential for the Company's Manocept(TM) platform imaging agents to diagnose and stage rheumatoid arthritis (RA) and Kaposi's Sarcoma (KS). The data were presented by scientific collaborators at the 2014 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis, MO.
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at:
Navidea Biopharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2014 Global Healthcare Conference June 2-5, 2014 at the Grand Hyatt in New York City, NY. Dr. Tulip will present a Company update on Thursday, June 5, 2014 at 1:30 PM EDT.
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Tue Jul 29, 8:37AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. EDT.
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
Business Wire - Thu Jul 17, 2:44PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. Approximately 79 percent of outstanding shares were represented at the meeting.
Navidea Joins Essex Woodland's Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases
Business Wire - Wed Jul 16, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has formed a joint enterprise with Essex Woodlands-backed Rheumco, LLC, to develop and commercialize radiolabeled diagnostics and therapeutics for rheumatologic and arthritic diseases. The joint enterprise, called R-NAV, LLC, will combine Navidea's proprietary Manocept CD206 macrophage targeting platform and Rheumco's proprietary Tin-117m radioisotope technology to focus on leveraging the platforms across several indications with high unmet medical need:
Accuray Shows Continued Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:25PM CDT
We are also encouraged about Accuray's (ARAY) narrower loss in the 2014-third quarter and upgraded guidance for total revenue for the full fiscal year.
Cyberonics Poised on Favorable Market Trend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 2:20PM CDT
On July 2, we issued an updated research report on Cyberonics Inc. (CYBX).
Thoratec Acquires Irish Implant Systems Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 12:40PM CDT
Thoratec Corp. (THOR) expects to enjoy long-term tax benefits from the Apica acquisition.
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014
Business Wire - Wed Jul 02, 4:06PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 from 8:00 to 9:00 am EDT in New York City.
ABIOMED Acquires Germany's Medical Device Maker - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 12:30PM CDT
The acquisition will solidify ABIOMED's (ABMD) position in intellectual property for axial and expandable pump capabilities
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael Goldberg, M.D., Interim Chief Executive Officer, will participate at the 9th Annual JMP Securities Healthcare Conference June 24-25, 2014 at the Westin New York Grand Central in New York City, NY. Navidea's presentation is on Tuesday, June 24, 2014 at 2:00 PM EDT.
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Navidea Biopharmaceuticals Inc. Shares Briefly Spiked Lower
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
U.S. FDA Approves Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy
Business Wire - Fri Jun 13, 11:26AM CDT
--- Lymphoseek now available for multiple patient populations using existing reimbursement codes -
Biotech Stock Mailbag: Vanda, Navidea, Provectus
at The Street - Fri Jun 13, 7:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Navidea (NAVB) Worth Watching: Stock Up 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:46AM CDT
Navidea (NAVB) was a big mover last session, with shares rising over 7% on the day.
Why Navidea Biopharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 2:35PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Navidea Biopharmaceuticals , a developer...
Navidea Biopharmaceuticals' Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
Business Wire - Wed Jun 11, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from a post-hoc analysis of patient data from the Company's Phase 3 clinical trial (NEO3-06) of Lymphoseek in head and neck cancer. The ability of Lymphoseek to localize in sentinel lymph nodes is based on its ability to target specific CD206 mannose receptor sites in macrophages, a type of immune cell which resides in high concentration in lymph nodes. In the NEO3-06 Phase 3 study, Lymphoseek localization to lymph nodes showed a strong correlation with a full regional lymph node dissection and pathology analysis with a low false negative rate, a priority in identifying sentinel nodes. Lymphoseek was also observed to home preferentially to pathology-positive nodes at a higher rate than pathology-negative nodes. These results suggest that Lymphoseek not only effectively targets sentinel lymph nodes, but further that its ability to highlight tumor-positive lymph nodes may be augmented mechanistically by the recruitment of macrophages to cancer-harboring lymph nodes.
Navidea Biopharmaceuticals Announces Positive Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Results on Injection Timing and Surgery Across Multiple Solid Tumor Types
Business Wire - Tue Jun 10, 3:30PM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from combined analyses of Phase 3 clinical trials that evaluated Lymphoseek(R) efficacy in lymphatic mapping for identifying pathology-positive lymph nodes across multiple solid tumor types: melanoma, breast cancer and head and neck squamous cell carcinoma. The results indicated that Lymphoseek sensitivity for sentinel lymph node mapping was consistent across the tumor type studies, regardless of whether surgery was conducted on the same day as, or on the day after injection of Lymphoseek. Additionally, for patients with head and neck cancer, Lymphoseek demonstrated a low false negative rate (FNR) of 2.6% (4.6% for same day injection before surgery and 0.0% FNR in patients injected the day prior to surgery). Results from the study comprise part of an sNDA filing for Lymphoseek which is under review by the U.S. Food and Drug Administration.
Navidea Announces Data Demonstrating Potential of Manocept(TM) Platform to Diagnose Rheumatoid Arthritis and Kaposi's Sarcoma
Business Wire - Tue Jun 10, 7:01AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from three research studies performed with collaborators that demonstrate the potential for the Company's Manocept(TM) platform imaging agents to diagnose and stage rheumatoid arthritis (RA) and Kaposi's Sarcoma (KS). The data were presented by scientific collaborators at the 2014 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis, MO.
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at:
Navidea Biopharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 29, 6:30AM CDT
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2014 Global Healthcare Conference June 2-5, 2014 at the Grand Hyatt in New York City, NY. Dr. Tulip will present a Company update on Thursday, June 5, 2014 at 1:30 PM EDT.
